Melanotan II adverse-effect reports
Published reports about Melanotan II include small early human studies, individual case reports and regulator warnings about unregulated products. These sources answer different questions. They do not establish how frequently an event occurs across all products marketed under the name.
A useful reading separates what happened, how the material was identified and what the authors could conclude about causality. The absence of a reported event in a small study is not proof that the event cannot occur.
What case reports can establish
A case report documents an observation in one person or a small group. It can identify a concern worth investigating, but it usually cannot estimate a population-level risk. Unknown product composition, other exposures and incomplete information can limit interpretation.
Reports associated with unregulated melanotan products should therefore retain the authors' description of the material. Do not silently recast an internet product as a verified laboratory reference standard or assume that a label proves its contents.
Product composition is a separate question
In an August 2026 advisory, Australia's TGA reported inconsistent Melanotan II content across five tested nasal-spray bottles from a named product line. This is a finding about the seized products in that investigation. It is not an analytical result for an EPS vial.
The example illustrates why the biological question and the analytical question need separate evidence. A report of symptoms does not establish chemical identity; a chemical measurement does not establish suitability for use in people.
Keep the evidence categories visible
| Source | Useful information | Main limit |
|---|---|---|
| Small clinical study | Observations in its selected participants | Limited size and study conditions |
| Case report | A documented event and clinical history | Cannot establish event frequency |
| Product investigation | Results for tested samples | Does not cover all products or batches |
| Research COA | The tests and sample stated on the report | Does not establish a clinical safety profile |
For the molecular background, read Melanotan II research and the comparison with Melanotan I. The EMA assessment of Scenesse concerns the authorised afamelanotide product, a separate molecule and formulation context; it is not an authorisation for Melanotan II.
Anyone experiencing symptoms after using an unregulated product should seek medical advice. EPS materials are listed for in-vitro laboratory research, and no EPS batch certificate is currently published.